Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.165
-0.005 (-0.43%)
Sep 8, 2026, 12:38 PM EDT - Market open

Metagenomi Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-93.46-87.87-78.06-68.26-43.59-21.44
Depreciation & Amortization
5.165.325.414.211.730.39
Asset Writedown & Restructuring Costs
0.960.51.040.020.28-
Loss (Gain) From Sale of Investments
-1.73-1.713.02-11.34-1.22-2.56
Stock-Based Compensation
10.5211.8516.26.921.960.38
Other Operating Activities
5.225.112.983.471.081.24
Change in Accounts Receivable
0.870.951.19-1.18-1.27-
Change in Accounts Payable
-0.121.05-1.11-0.080.720.7
Change in Unearned Revenue
-11.17-21.1-46.8-30.365.6644.23
Change in Income Taxes
---3.271.731.54-
Change in Other Net Operating Assets
-1.74-3-9.693.42.841.33
Operating Cash Flow
-85.49-88.89-109.07-91.4129.7224.26
Operating Cash Flow Growth
----22.54%-

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.31-0.57-3.11-9.81-13.98-2.9
Sale of Property, Plant & Equipment
-0.04----
Investment in Securities
97.19104.07-85.0455.55-108.22-71.41
Investing Cash Flow
96.88103.53-88.1645.73-122.2-74.32

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-----29.97
Net Debt Issued (Repaid)
-----29.97
Issuance of Common Stock
0.170.284.01---
Other Financing Activities
-0.24-0.56--3.28--
Financing Cash Flow
-0.07-0.3684.011.01239.5939.92

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
11.3214.28-113.22-44.66147.12-10.14

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-85.8-89.47-112.19-101.2215.7521.35
Free Cash Flow Growth
-----26.26%-
Free Cash Flow Margin
-632.67%-354.88%-214.53%-226.17%91.55%8787.65%
Free Cash Flow Per Share
-2.29-2.40-3.40-29.734.633.75
Levered Free Cash Flow
-50.95-53.31-73.35-31.65-19.71-
Unlevered Free Cash Flow
-50.95-53.31-73.35-31.65-19.65-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
----2.161.45
Cash Income Tax Paid
--2.243.512.25--
Change in Working Capital
-12.16-22.09-59.67-26.4369.4946.26
SEC Filings: 10-K · 10-Q